Eladio A. Velasco-Sampedro is a Senior Researcher at the Institute of Biomedicine and Molecular Genetics, Spanish National Research Council (CSIC), Valladolid, Spain. He holds a PhD in Biological Sciences from the Autonomous University of Madrid (1996). Since 1989 he has been involved in the research and molecular diagnosis of hereditary diseases, including Spinal Muscular Atrophy (PhD Thesis), Neurofibromatosis type I, Adult Polycystic Kidney Disease, and Lynch Syndrome, among others, and since 2000 he has focused his studies on hereditary breast and ovarian cancer and their susceptibility genes. He has been employed as a postdoctoral researcher in the Hereditary Cancer Prevention Program of the Junta de Castilla y León (2000-2008). Since taking up his position as a senior scientist at the CSIC in 2008, he has headed the Splicing and Genetic Susceptibility to Cancer group at the Institute of Molecular Biology and Genetics, whose main line of research is directed towards studying the correlation between aberrant splicing of tumor suppressor genes (mainly BRCA1 and BRCA2) and hereditary breast/ovarian cancer. He has obtained a patent on the splicing reporter plasmid pSAD (Splicing and Disease), from which he has developed and optimized hybrid minigene technology. He has received the 3M award for innovation in the area of Health (2008) and the Junta de Castilla y León Award from the Royal Academy of Medicine and Surgery of Valladolid (2009).